Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DM005 in Patients With Advanced Solid Tumors
NCT06515990Phase 2Recruiting
- Sponsor
- Doma Pharmaceutical Technology
- Start
- Oct 2024
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of DM005 in solid tumor (9 arms), sponsored by Doma Pharmaceutical Technology. Primary endpoints: Dose-limiting Toxicities at 12 months and Maximum Tolerated Dose at 12 months. Started Oct 2024; status: recruiting.
02
Drugs
DM005
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06515990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06515990.